Gilead Sciences | GILD - Ordinary Share Capital


Gilead Sciences reported $1.24B in Ordinary Share Capital for its fiscal quarter ending in March of 2026.





Ordinary Share Capital Change Date
AbbVie USD 1.77B 1.75B Jun/2025
Agios Pharmaceuticals USD 59.34M 892K Mar/2026
ALKERMES USD 166.46M 855K Mar/2026
Alnylam Pharmaceuticals USD 133.44M 1.07M Mar/2026
Amgen USD 540M 1000K Mar/2026
Biogen USD 146.7M 200K Sep/2025
BioMarin Pharmaceutical USD 193.27M 969K Mar/2026
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Coherus Biosciences USD 121.16M 4.92M Dec/2025
Eli Lilly USD 943.5M 3.33M Mar/2026
Gilead Sciences USD 1.24B 1000K Mar/2026
GlaxoSmithKline GBP 4.05B 20.6M Mar/2026
Glaxosmithkline GBP 4.08B 49.43M Dec/2025
Incyte USD 199.95M 1.49M Mar/2026
J&J USD 2.41B 1.74M Dec/2025
Merck USD 2.47B 12.72M Dec/2025
Moderna USD 391M 2M Sep/2025
Neurocrine Biosciences USD 100.6M 500K Mar/2026
Novartis USD 1.91B 60K Mar/2026
Pfizer USD 5.7B 13M Mar/2026
PTC Therapeutics USD 81.47M 1.54M Dec/2025
Puma Biotechnology USD 5K 0 Jun/2024
Regeneron Pharmaceuticals USD 105M 300K Mar/2026
Sanofi EUR 1.21B 8.25M Mar/2026
Sarepta Therapeutics USD 105.57M 607K Mar/2026
United Therapeutics USD 42.16M 1.49M Mar/2026
Vertex Pharmaceuticals USD 254.2M 200K Mar/2026